The US Food and Drug Administration is establishing a Pharmaceutical Supply Chain Governance Board to start in September on advancing the agency’s efforts to increase the transparency of pharmaceutical supply chains and protect them from emergencies like the coronavirus pandemic.
Building on the activities of the agency’s drug shortages program and other efforts already in place, the board will facilitate and coordinate supply chain initiatives across the Center for Drug Evaluation and Research and provide strategic
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?